Hyloris Pharmaceuticals (XBRU:HYL) Gross Margin % : 97.16% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Hyloris Pharmaceuticals's Gross Profit for the six months ended in Dec. 2023 was €1.61 Mil. Hyloris Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was €1.65 Mil. Therefore, Hyloris Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 97.16%.

The historical rank and industry rank for Hyloris Pharmaceuticals's Gross Margin % or its related term are showing as below:

XBRU:HYL' s Gross Margin % Range Over the Past 10 Years
Min: 17.14 Med: 55.4 Max: 96.81
Current: 96.7

During the past 8 years, the highest Gross Margin % of Hyloris Pharmaceuticals was 96.81%. The lowest was 17.14%. And the median was 55.40%.

XBRU:HYL's Gross Margin % is ranked better than
95.25% of 737 companies
in the Biotechnology industry
Industry Median: 59.4 vs XBRU:HYL: 96.70

Hyloris Pharmaceuticals had a gross margin of 97.16% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Hyloris Pharmaceuticals was 39.30% per year.

Hyloris Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Hyloris Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Gross Margin % Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

27.47

17.14

96.54

96.81

96.70

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Margin %	Get a 7-Day Free Trial							97.12	94.09	98.28	96.03	97.16

Competitive Comparison of Hyloris Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Gross Margin % falls into.

Hyloris Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Hyloris Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	2.7	/	2.814
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(2.814 - 0.093)	/	2.814
	=	96.70 %

Hyloris Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.6	/	1.654
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(1.654 - 0.047)	/	1.654
	=	97.16 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Hyloris Pharmaceuticals (XBRU:HYL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hyloris Pharmaceuticals had a gross margin of 97.16% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Hyloris Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.